Headquartered in Cambridge, MA Fiscal year ends December NASDAQ: SRRK scholarrock.com
Scholar Rock Holding Corporation is a late-stage biopharmaceutical company focused on developing and commercializing therapies for rare, severe, and debilitating neuromuscular diseases. The company's proprietary platform centers on myostatin biology, developing novel monoclonal antibodies that modulate protein growth factors with high selectivity. Its lead product candidate, apitegromab, is an investigational fully human monoclonal antibody designed to inhibit myostatin activation in skeletal muscle, currently under FDA BLA review for spinal muscular atrophy (SMA) with a September 30, 2026 PDUFA date. Apitegromab is also being evaluated in facioscapulohumeral muscular dystrophy (FSHD) in a Phase 2 trial. The company's pipeline also includes SRK-439, a next-generation subcutaneously administered myostatin inhibitor currently in Phase 1 testing. Scholar Rock is pre-revenue, with operations focused on clinical development, regulatory submissions, and commercial readiness for a potential U.S. launch of apitegromab. The company trades on NASDAQ under the ticker SRRK. Updated
Eli Lilly (NYSE:LLY | LLY Price Prediction) is the stock everyone wants to talk about, and the reasons are obvious: Mounjaro revenue jumped 125% to $8.66 billion last quarter, the company raised…
In the past week or so, a fintech firm and two biotechs saw some huge insider buying. However, these were not the only notable insider purchases recently.
People don’t like to throw money into a sinking ship, and by that logic, insider buys in Wall Street can be an easy way to gauge how well a company might do…
Scholar Rock Holding Corporation is a late-stage biopharmaceutical company focused on developing and commercializing therapies for rare, severe, and debilitating neuromuscular diseases.
The Wall Street consensus 12-month price target for SRRK is $70.44.
